キナーゼ阻害剤の世界市場2019-2027

◆英語タイトル:Kinase Inhibitors - Global Market Outlook (2019-2027)
◆商品コード:SMRC20JL256
◆発行会社(リサーチ会社):Stratistics MRC
◆発行日:2020年6月30日
◆ページ数:160
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD4,150 ⇒換算¥435,750見積依頼/購入/質問フォーム
Five UserUSD5,250 ⇒換算¥551,250見積依頼/購入/質問フォーム
Global Site LicenseUSD7,500 ⇒換算¥787,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はStratistics MRC社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Stratistics MRC社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

本調査レポートでは、キナーゼ阻害剤の世界市場を広く調査・分析し、エグゼクティブサマリー、序論、市場動向分析、ファイブフォース分析、種類別(受容体型チロシンキナーゼ阻害剤、非受容体型チロシンキナーゼ阻害剤、血管新生阻害剤、プロテインキナーゼC阻害剤、その他)分析、流通チャンネル別分析、用途別分析、エンドユーザー別分析、地域別分析、主要な市場開拓、企業情報など、今後の市場展望をまとめております。
・エグゼクティブサマリー
・序論
・市場動向分析
・ファイブフォース分析
・キナーゼ阻害剤の世界市場規模:種類別(受容体型チロシンキナーゼ阻害剤、非受容体型チロシンキナーゼ阻害剤、血管新生阻害剤、プロテインキナーゼC阻害剤、その他)
・キナーゼ阻害剤の世界市場規模:流通チャンネル別
・キナーゼ阻害剤の世界市場規模:用途別
・キナーゼ阻害剤の世界市場規模:エンドユーザー別
・キナーゼ阻害剤の世界市場規模:地域別
・主要な市場開拓
・企業情報
【レポートの概要】

Accord ing to Stratistics MRC, the Global Kinase Inhibitors Market is accounted for $40.41 billion in 2019 and is expected to reach $64.90 billion by 2027 growing at a CAGR of 6.1% during the forecast period. Some of the key factors propelling the market growth include rise in awareness about kinase inhibitors, surge in product approvals, increase in incident of cancer diseases, and increase in investment from pharmaceutical companies. However, cost of treatment and lack of funds in conducting research are likely to restraint the market. In addition, increase in adoption of kinase inhibitors for newer applications, and emerging economies such as China, India and others, will create new opportunities for global kinase inhibitors market.

Kinase inhibitors are considered as specific enzymes that help in preventing the process of cell division and the growth of cancerous cells. These inhibitors are easy to use and are handy while treating cancer patients by blocking the signals that alert the cancer cells to grow. With the help of research and development activities in the cancer treatments, several innovations, and advanced therapeutics have been introduced. However, the results of these drugs and treatments are considered partial, palliative, and unpredictable at times. Kinase inhibitors are being highly publicized as a potential treatment for alopecia areata (AA).

By application, the oncology segment is expected to grow at the significant rate during the forecast period. Large number of approved drugs along with rich product pipeline for cancer treatment is anticipated to fuel the growth of the segment in the near future. Based on data from clinicaltrials.gov last updated on January 2020, over 75 kinase inhibitor drugs are in various phases of clinical trials for the application of oncology. On the basis of geography, North America is anticipated to have considerable market growth during the forecast period, due to rise in awareness about new drugs for treatment, availability of all major companies in the region, the introduction of new drugs, and high prevalence of cases in U.S.

Some of the key players in kinase inhibitors market include Меrсk Ѕеrоnо Ѕа, Nоvаrtіѕ Іntеrnаtіоnаl Аg, Incyte Corporation, Glaxo SmithKline, Суtrх Соrроrаtіоn, Оѕі Рhаrmасеutісаlѕ Llс, AstraZeneca, Eisai Co., Ltd., Bristol-Myers Squibb, Bayer AG, Pfizer Inc., Takeda Pharmaceutical Company Limited, Boehringer Ingelheim GmbH, Eisai Co., Ltd., Johnson & Johnson, Еtоn Віоѕсіеnсе Іnс., and F. Hoffmann-La Roche Ltd.

Types Covered:
• Receptor Tyrosine Kinase Inhibitors
• Non-receptor Tyrosine Kinase Inhibitors
• Angiogenesis Inhibitors
• Protein Kinase C Inhibitors
• RHO Kinase Inhibitors
• Multikinase inhibitors
• Serine/Threonine Kinase Inhibitors
• Tyrosin kinase inhibitors (TKI)
• Threonine kinase inhibitor
• mTOR Kinase Inhibitors
• BRAF Inhibitors
• Cyclin Dependant Kinase Inhibitor
• Aurora Kinase Inhibitors
• MAP/MEK Kinase Inhibitors
• Humanized Monoclonal Antibody
• Chimeric Monoclonal Antibody
• JNK Inhibitors
• PI3K Inhibitors
• Other Types

Distribution Channels Covered:
• Independent Pharmacies
• Hospital Pharmacies
• Online Pharmacies

Applications Covered:
• Inflammatory Diseases
• Oncology

End Users Covered:
• Scientific Research Labs
• Hospitals
• Academic Institutes
• Healthcare Facilities
• Pharmaceutical Companies
• Private and Government Research Institutes

Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o France
o Italy
o UK
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2018, 2019, 2020, 2024 and 2027
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic analysis: Drivers and Constraints, Product/Technology Analysis, Porter’s five forces analysis, SWOT analysis, etc.
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client’s interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

【レポートの目次】

1 Executive Summary

2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions

3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Application Analysis
3.7 End User Analysis
3.8 Emerging Markets
3.9 Impact of Covid-19

4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Kinase Inhibitors Market, By Type
5.1 Introduction
5.2 Receptor Tyrosine Kinase Inhibitors
5.2.1 Platelet-derived Growth Factor Receptors (PDGFR)
5.2.2 Vascular Endothelial Growth Factor Receptor (VEGFR)
5.2.3 Anaplastic lymphoma kinase (ALK)
5.2.4 Human Epidermal Growth Factor Receptor 2 (HER2)
5.2.5 Estimated Glomerular Filtration Rate (EGFR)
5.3 Non-receptor Tyrosine Kinase Inhibitors
5.3.1 Mesenchymal Epithelial Transition Growth Factor (c-MET)
5.3.2 Spleen Tyrosine Kinase (SYK) Inhibitors
5.3.3 Bruton’s Tyrosine Kinase (BTK) Inhibitors
5.3.4 BCR-ABL
5.3.5 Janus Kinase (JAK) Inhibitor
5.4 Angiogenesis Inhibitors
5.5 Protein Kinase C Inhibitors
5.6 RHO Kinase Inhibitors
5.7 Multikinase inhibitors
5.8 Serine/Threonine Kinase Inhibitors
5.9 Tyrosin kinase inhibitors (TKI)
5.10 Threonine kinase inhibitor
5.11 mTOR Kinase Inhibitors
5.12 BRAF Inhibitors
5.13 Cyclin Dependant Kinase Inhibitor
5.14 Aurora Kinase Inhibitors
5.15 MAP/MEK Kinase Inhibitors
5.16 Humanized Monoclonal Antibody
5.17 Chimeric Monoclonal Antibody
5.18 JNK Inhibitors
5.19 PI3K Inhibitors
5.20 Other Types
5.20.1 Monoclonal Antibody Kinase Inhibitor

6 Global Kinase Inhibitors Market, By Distribution Channel
6.1 Introduction
6.2 Independent Pharmacies
6.3 Hospital Pharmacies
6.4 Online Pharmacies

7 Global Kinase Inhibitors Market, By Application
7.1 Introduction
7.2 Inflammatory Diseases
7.3 Oncology
7.3.1 Lung Cancer
7.3.2 Renal Cell Cancer
7.3.3 Breast Cancer

8 Global Kinase Inhibitors Market, By End User
8.1 Introduction
8.2 Scientific Research Labs
8.3 Hospitals
8.4 Academic Institutes
8.5 Healthcare Facilities
8.6 Pharmaceutical Companies
8.7 Private and Government Research Institutes

9 Global Kinase Inhibitors Market, By Geography
9.1 Introduction
9.2 North America
9.2.1 US
9.2.2 Canada
9.2.3 Mexico
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 Italy
9.3.4 France
9.3.5 Spain
9.3.6 Rest of Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 New Zealand
9.4.6 South Korea
9.4.7 Rest of Asia Pacific
9.5 South America
9.5.1 Argentina
9.5.2 Brazil
9.5.3 Chile
9.5.4 Rest of South America
9.6 Middle East & Africa
9.6.1 Saudi Arabia
9.6.2 UAE
9.6.3 Qatar
9.6.4 South Africa
9.6.5 Rest of Middle East & Africa

10 Key Developments
10.1 Agreements, Partnerships, Collaborations and Joint Ventures
10.2 Acquisitions & Mergers
10.3 New Product Launch
10.4 Expansions
10.5 Other Key Strategies

11 Company Profiling
11.1 Меrсk Ѕеrоnо Ѕа
11.2 Nоvаrtіѕ Іntеrnаtіоnаl Аg
11.3 Incyte Corporation
11.4 Glaxo SmithKline
11.5 Суtrх Соrроrаtіоn
11.6 Оѕі Рhаrmасеutісаlѕ Llс
11.7 AstraZeneca, Eisai Co., Ltd.
11.8 Bristol-Myers Squibb
11.9 Bayer AG
11.10 Pfizer Inc.
11.11 Takeda Pharmaceutical Company Limited
11.12 Boehringer Ingelheim GmbH
11.13 Eisai Co., Ltd.
11.14 Johnson & Johnson
11.15 Еtоn Віоѕсіеnсе Іnс.
11.16 F. Hoffmann-La Roche Ltd

List of Tables
Table 1 Global Kinase Inhibitors Market Outlook, By Region (2018-2027) ($MN)
Table 2 Global Kinase Inhibitors Market Outlook, By Type (2018-2027) ($MN)
Table 3 Global Kinase Inhibitors Market Outlook, By Receptor Tyrosine Kinase Inhibitors (2018-2027) ($MN)
Table 4 Global Kinase Inhibitors Market Outlook, By Platelet-derived Growth Factor Receptors (PDGFR) (2018-2027) ($MN)
Table 5 Global Kinase Inhibitors Market Outlook, By Vascular Endothelial Growth Factor Receptor (VEGFR) (2018-2027) ($MN)
Table 6 Global Kinase Inhibitors Market Outlook, By Anaplastic lymphoma kinase (ALK) (2018-2027) ($MN)
Table 7 Global Kinase Inhibitors Market Outlook, By Human Epidermal Growth Factor Receptor 2 (HER2) (2018-2027) ($MN)
Table 8 Global Kinase Inhibitors Market Outlook, By Estimated Glomerular Filtration Rate (EGFR) (2018-2027) ($MN)
Table 9 Global Kinase Inhibitors Market Outlook, By Non-receptor Tyrosine Kinase Inhibitors (2018-2027) ($MN)
Table 10 Global Kinase Inhibitors Market Outlook, By Mesenchymal Epithelial Transition Growth Factor (c-MET) (2018-2027) ($MN)
Table 11 Global Kinase Inhibitors Market Outlook, By Spleen Tyrosine Kinase (SYK) Inhibitors (2018-2027) ($MN)
Table 12 Global Kinase Inhibitors Market Outlook, By Bruton’s Tyrosine Kinase (BTK) Inhibitors (2018-2027) ($MN)
Table 13 Global Kinase Inhibitors Market Outlook, By BCR-ABL (2018-2027) ($MN)
Table 14 Global Kinase Inhibitors Market Outlook, By Janus Kinase (JAK) Inhibitor (2018-2027) ($MN)
Table 15 Global Kinase Inhibitors Market Outlook, By Angiogenesis Inhibitors (2018-2027) ($MN)
Table 16 Global Kinase Inhibitors Market Outlook, By Protein Kinase C Inhibitors (2018-2027) ($MN)
Table 17 Global Kinase Inhibitors Market Outlook, By RHO Kinase Inhibitors (2018-2027) ($MN)
Table 18 Global Kinase Inhibitors Market Outlook, By Multikinase inhibitors (2018-2027) ($MN)
Table 19 Global Kinase Inhibitors Market Outlook, By Serine/Threonine Kinase Inhibitors (2018-2027) ($MN)
Table 20 Global Kinase Inhibitors Market Outlook, By Tyrosin kinase inhibitors (TKI) (2018-2027) ($MN)
Table 21 Global Kinase Inhibitors Market Outlook, By Threonine kinase inhibitor (2018-2027) ($MN)
Table 22 Global Kinase Inhibitors Market Outlook, By mTOR Kinase Inhibitors (2018-2027) ($MN)
Table 23 Global Kinase Inhibitors Market Outlook, By BRAF Inhibitors (2018-2027) ($MN)
Table 24 Global Kinase Inhibitors Market Outlook, By Cyclin Dependant Kinase Inhibitor (2018-2027) ($MN)
Table 25 Global Kinase Inhibitors Market Outlook, By Aurora Kinase Inhibitors (2018-2027) ($MN)
Table 26 Global Kinase Inhibitors Market Outlook, By MAP/MEK Kinase Inhibitors (2018-2027) ($MN)
Table 27 Global Kinase Inhibitors Market Outlook, By Humanized Monoclonal Antibody (2018-2027) ($MN)
Table 28 Global Kinase Inhibitors Market Outlook, By Chimeric Monoclonal Antibody (2018-2027) ($MN)
Table 29 Global Kinase Inhibitors Market Outlook, By JNK Inhibitors (2018-2027) ($MN)
Table 30 Global Kinase Inhibitors Market Outlook, By PI3K Inhibitors (2018-2027) ($MN)
Table 31 Global Kinase Inhibitors Market Outlook, By Other Types (2018-2027) ($MN)
Table 32 Global Kinase Inhibitors Market Outlook, By Monoclonal Antibody Kinase Inhibitor (2018-2027) ($MN)
Table 33 Global Kinase Inhibitors Market Outlook, By Distribution Channel (2018-2027) ($MN)
Table 34 Global Kinase Inhibitors Market Outlook, By Independent Pharmacies (2018-2027) ($MN)
Table 35 Global Kinase Inhibitors Market Outlook, By Hospital Pharmacies (2018-2027) ($MN)
Table 36 Global Kinase Inhibitors Market Outlook, By Online Pharmacies (2018-2027) ($MN)
Table 37 Global Kinase Inhibitors Market Outlook, By Application (2018-2027) ($MN)
Table 38 Global Kinase Inhibitors Market Outlook, By Inflammatory Diseases (2018-2027) ($MN)
Table 39 Global Kinase Inhibitors Market Outlook, By Oncology (2018-2027) ($MN)
Table 40 Global Kinase Inhibitors Market Outlook, By Lung Cancer (2018-2027) ($MN)
Table 41 Global Kinase Inhibitors Market Outlook, By Renal Cell Cancer (2018-2027) ($MN)
Table 42 Global Kinase Inhibitors Market Outlook, By Breast Cancer (2018-2027) ($MN)
Table 43 Global Kinase Inhibitors Market Outlook, By End User (2018-2027) ($MN)
Table 44 Global Kinase Inhibitors Market Outlook, By Scientific Research Labs (2018-2027) ($MN)
Table 45 Global Kinase Inhibitors Market Outlook, By Hospitals (2018-2027) ($MN)
Table 46 Global Kinase Inhibitors Market Outlook, By Academic Institutes (2018-2027) ($MN)
Table 47 Global Kinase Inhibitors Market Outlook, By Healthcare Facilities (2018-2027) ($MN)
Table 48 Global Kinase Inhibitors Market Outlook, By Pharmaceutical Companies (2018-2027) ($MN)
Table 49 Global Kinase Inhibitors Market Outlook, By Private and Government Research Institutes (2018-2027) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[キナーゼ阻害剤の世界市場2019-2027]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆